ArticleBiomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals2015
Comparing the prognostic performance of ASSIST to interleukin-6 and procalcitonin in patients with severe sepsis or septic shock.
Article in Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.
- Plasma interleukin-6 concentration for the diagnosis of sepsis in critically ill adults.The Cochrane database of systematic reviews · 2019Pooled it
- A prospective observational cohort study to identify inflammatory biomarkers for the diagnosis and prognosis of patients with sepsis.Journal of intensive care · 2022Article
- Hemofiltration in Patients with Severe Acute Pancreatitis (Review).Sovremennye tekhnologii v meditsine · 2020Review
- An Enrichment Strategy For Sepsis Clinical Trials.Shock (Augusta, Ga.) · 2016Article
- Emerging infection and sepsis biomarkers: will they change current therapies?Expert review of anti-infective therapy · 2016Review
- Designing phase 3 sepsis trials: application of learned experiences from critical care trials in acute heart failure.Journal of intensive care · 2016Review
- Sepsis without SIRS is still sepsis.Annals of translational medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 7 institutions in 3 countries.
Funding
Abstract
contextWe recently derived and validated a multi-biomarker-based model (ASSIST) to stratify patients with sepsis based on initial mortality risk.
objectiveThe objective of this study was to compare the performance of ASSIST to interleukin-6 (IL6) and procalcitonin (PCT).
methodsThe area-under-the-receiver operating characteristic curve for predicting 28-d mortality using ASSIST was compared with that of IL6 (n = 452) and PCT (n = 235).
resultsThe area under the curve for ASSIST was greater than that of IL6 and PCT.
conclusionsASSIST estimated the probability of mortality more reliably than IL6 and PCT in this cohort of patients with sepsis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.